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Gaucher disease (GD) is the most common form of sphingolipidosis and is caused by a defect of h-glucosidase (h-Glu). A carbohydrate
mimic N-octyl-h-valienamine (NOV) is an inhibitor of h-Glu. When applied to cultured GD fibroblasts with F213I h-Glu mutation, NOV
increased the protein level of the mutant enzyme and up-regulated cellular enzyme activity. The maximum effect of NOVwas observed in F213I
homozygous cells in whichNOV treatment at 30 AMfor 4 days caused a f 6-fold increase in the enzyme activity, up to f 80%of the activity in
control cells. NOV was not effective in cells with other h-Glu mutations, N370S, L444P, 84CG and RecNciI. Immunofluorescence and cell
fractionation showed localization of the F213I mutant enzyme in the lysosomes of NOV-treated cells. Consistent with this, NOV restored
clearance of 14C-labeled glucosylceramide in F213I homozygous cells. F213I mutant h-Glu rapidly lost its activity at neutral pH in vitro and this
pH-dependent loss of activity was attenuated byNOV. These results suggest that NOVworks as a chemical chaperone to accelerate transport and
maturation of F213I mutant h-Glu and may suggest a therapeutic value of this compound for GD.
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Qingdao University, Qingdao, Shandong 266021, PR China.1. IntroductionGaucher disease (GD) is an inherited lipid storage
disorder, characterized by lysosomal accumulation of glu-
cocerebroside (glucosylceramide; GlcCer) in monocyte-
macrophage cells [1]. It is caused by a defect of acid h-
glucosidase (h-Glu; glucocerebrosidase EC 3.2.1.45).
Patients with GD exhibit hepatosplenomegaly, anemia, bone
lesions and respiratory failure, with or without progressive
neurological symptoms. Patients without neurological
symptoms are classified as type 1, whereas those with
neurological symptoms are classified into type 2 (acute
infantile form) and type 3 (juvenile form).
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replacement and substrate depletion. Enzyme replacement
has been achieved by intravenous administration of mac-
rophage-targeted recombinant h-Glu [2] and it has been
proven to be quite effective for visceral, hematologic and
skeletal abnormalities [3,4]. Unfortunately, the efficacy to
neurological manifestations of this therapy is, if any,
limited [5–7]. A high cost as well as necessity to continue
the infusion every 2 weeks is not negligible, when indi-
cation of enzyme replacement is considered in practice [4].
Substrate depletion has been achieved by oral administra-
tion of N-butyl-deoxynojirimycin, which inhibits glucosyl-
transferase and decreases substrate biosynthesis. This
therapy has been reported to be beneficial for non-neuro-
pathic GD [8,9].
We have proposed a novel therapeutic strategy for
glycolipid storage disorders to accelerate transport and
maturation of mutant enzymes by using enzyme inhib-
itors as a chemical chaperone. This strategy was first
applied to Fabry disease (a-galactosidase A [a-Gal A]
deficiency) and we found that 1-deoxy-galactonojirimycin
(DGJ), an inhibitor of a-Gal A, markedly enhanced
activity of mutant enzymes in lymphoblasts from Fabry
patients [10]. Although up-regulation of enzyme activity
by an inhibitor appeared paradoxical, evidence was
presented that DGJ prevented pH-dependent degradation
of mutant a-Gal A at the site of its synthesis [i.e., the
endoplasmic reticulum (ER)]. With the aid of DGJ,
mutant a-Gal A escaped the ER quality control system
and was transported to the lysosome where it is stabi-
lized because of the acidic condition and restored cellular
enzyme activity. This strategy was then tested in GM1-
galactosidosis [h-galactosidase (h-Gal) deficiency] and
we found that DGJ as well as another derivative N-(n-
butyl)-deoxy-galactonojirimycin could up-regulate activity
of mutant human h-Gal expressed in fibroblasts from h-
Gal knockout mice [11]. In pursuit of the same thera-
peutic strategy, Sawkar et al. [12] reported that an
inhibitor of h-Glu, N-(n-nonyl)-deoxynojirimaycin (NN-
DNJ) up-regulated activity of N370S mutant h-Glu in
GD fibroblasts. Although it is yet to be tested whether
NN-DNJ can correct GlcCer accumulation in N370S GD
cells, their findings suggested that this strategy might be
extended to GD.
Valienamine is a synthetic carbohydrate mimic and we
have prepared various N-alkyl and N,N-dialkyl-h-valien-
amines in continuation of a chemical modification pro-
gram [13]. Among these substances, N-octyl-h-epi-
valienamine (NOEV) is an inhibitor of h-Gal and we
have provided evidence that NOEV worked as a chemical
chaperone to up-regulate mutant h-Gal activity both in
cultured cells and in mice [14]. N-octyl-h-valienamine
(NOV) is an isomer of NOEV and exerted the strongest
inhibition of h-Glu activity in the mouse liver [15]. The
purpose of the current studies was to test a possibility
that NOV could up-regulate mutant h-Glu activity incultured human cells. Preliminary findings of the current
studies have been reported [16].2. Materials and methods
2.1. Materials
Dulbecco’s Modified Eagle’s Medium (DMEM), fetal calf
serum (FCS) and dialyzed serum were obtained from Gib-
coBRL. NOV was synthesized in our laboratory (Central
Research Laboratories, Seikagaku). Stock solution of NOV
was prepared in H2O at 3 mM and stored at  20 jC. A
mouse monoclonal antibody against human h-Glu (clone
8E4, Ref. [17]) was a kind gift from Dr. Barranger JA. Rabbit
polyclonal anti-hexosaminidase A (HexA) has been de-
scribed [18]. Rabbit polyclonal anti-calnexin was from Cal-
biochem. [1-14C]Serine (1.85 GBq/mmol) was from
American Radiolabeled Chemicals (St. Louis, MO).
2.2. Cell culture
Human skin fibroblasts were cultured in DMEM/10%
FCS at 37 jC in 5% CO2. We used two lines of control cells
(H11, H34) and five lines of GD cells with h-Glu mutations
of 754A(F213I)/754A(F213I), 754A(F213I)/1448C(L444P),
1126G(N370S)/84GG, 1448C(L444P)/RecNciI, and
1448C(L444P)/1448C(L444P) [19]. 84GG causes premature
termination of the encoded protein and RecNciI causes amino
acid substitutions L444P and A456P [1]. Culture medium
was replaced every 2 days with fresh media supplemented
with or without NOV at the concentrations indicated.
2.3. Enzyme assays
Lysosomal enzyme activities in cell lysates were deter-
mined as described [14,18,20,21]. Briefly, cells were scraped
into ice-cold H2O (10
6/ml) and lysed by sonication. Insoluble
materials were removed by centrifugation at 12,000 g for
10 min at 4 jC and protein concentrations were determined
with a BCA microprotein assay kit (Piearce). Ten microliters
of the lysates was incubated at 37 jC with 20 Al of the
substrate solution in 0.1 M citrate buffer, pH 4.5. The
substrates were 4-methylumbelliferone-conjugated h-D-gal-
actopyranoside (for h-Gal, Ref. [14]), h-D-glucopyranoside
(for h-Glu, Ref. [20]), a-D-glucoside (for a-Glu, Ref. [21])
and N-acetyl-h-D-glucosaminide (for h-Hex, Ref. [18]). The
reaction was terminated by adding 1.0 ml of 0.2 M glycine
sodium hydroxide buffer (pH 10.7). One unit of enzyme
activity was defined as nanomoles of 4-methyl-umbelliferone
released per hour.
2.4. Western blotting
Cell lysates (20 Ag protein) were electrophoresed on a
10% SDS-PAGE and transferred to a PVDF membrane.
Fig. 1. Effects of NOV on lysosomal enzyme activities in lysates from
control human fibroblasts. (a) Chemical structures of NOV and its isomer
NOEV. (b) Dose dependence. Enzyme activity in H11 cell lysates was
determined in the absence or presence of increasing concentrations of NOV.
Each point represents means of triplicate determinations obtained in a single
experiment. Values were expressed as relative to activity in the absence of
NOV (100%). Values in the absence of NOV in this experiment were h-Glu
142, a-Glu 94 and h-Hex 5089 (units/mg protein). Similar results were
obtained in two other experiments.
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(1:500) or HexA (1:1000) and developed with an ECL
kit (Amersham Pharmacia). Densitometry was performed
by using an NIH image software.
2.5. Immunofluorescence
We used staining procedures described previously
[22]. Briefly, cells grown on cover glasses were fixed
with 4% paraformaldehyde and permiabilized with 1%
Triton X-100. Cells were incubated with anti-h-Glu
(1:100), followed by Alexa488-conjugated anti-mouse
IgG. Fluorescent images were collected by using a
Bio-Rad MRC1024 confocal laser microscope. For lo-
calization of lysosomes, cells were exposed to Lyso-
tracker Red (5 Ag/ml; Molecular Probe) for 1 h prior to
fixation.
2.6. Subcellular fractionation
Cell homogenates were fractionated by using Opti-prep
(Axis-Shield plc., Dundee, UK) as described [23]. Briefly,
cells were homogenized with a potter homogenizer in ice-
cold buffer [HEPES 10 mM pH 7.0, 1 mM EDTA, 1
mM EGTA supplemented with a protease inhibitor cock-
tail (Boehringer)]. Homogenates were overlaid on Opti-
prep and centrifuged at 100,000 g for 16 h at 4 jC.
Twelve fractions were recovered from the top and num-
bered accordingly.
2.7. Metabolic labeling of GlcCer
Cellular glycolipids were labeled with [14C]serine as
described [24]. Briefly, cells were cultured for 1 week in
dialyzed serum supplemented with essential amino acids
except for serine, and incubated with [14C]serine (1 ACi/
ml) for 3 days. The labeled cells were cultured in fresh
DMEM/10% FCS for 5 days with or without NOV. We
analyzed labeled lipids by high-performance thin layer
chromatography (HPTLC) as described [25]. In brief,
cells were harvested at the time indicated, and lipids
were extracted with chloroform/methanol (2:1 v/v) and
purified by an alkaline treatment. Neutral glycolipids
were purified by C18 affinity chromatography. HPTLC
was performed with chloroform/methanol/water (55:25:4)
as a developing solvent. Labeled lipids were visualized
by autoradiography (Fuji-BAS 2500: Fuji, Tokyo, Japan)
and densitometry was performed using an NIH image
software.
2.8. pH-dependent stability of b-Glu in vitro
Cell lysates were incubated in 0.1 M citrate-phosphate
buffer at pH5, 6 or 7 at 37jCfor the time indicated. Incubation
was terminated by the addition of 3 volumes of 0.2 M citrate-
phosphate buffer (pH 4.5), immediately followed by chillingon ice. The enzyme assay was done at pH 4.5 as described
above.3. Results
3.1. Inhibition of human b-Glu by NOV in vitro
Chemical structures of NOV and its isomer NOEV are
shown in Fig. 1a. NOV inhibited h-Glu activity in mouse
liver extracts with an IC50 value of 0.03 AM [15]. To test
whether it also works on the human enzyme, we deter-
mined h-Glu activity in lysates from control human
fibroblasts in the absence or presence of NOV. NOV
caused dose-dependent inhibition of h-Glu activity with
an IC50 value of 3 AM (Fig. 1b), indicating that it also
works on human h-Glu. NOV contains a C8 fatty acid acyl
moiety chain (Fig. 1a). A related compound with a C6
H. Lin et al. / Biochimica et Biophys222fatty acid acyl moiety chain inhibited human h-Glu with
an IC50 value of 30 AM (data not shown), suggesting that
the inhibitory activity can be regulated by the length of
this chain. NOV caused no inhibition of other lysosomal
enzymes a-Glu and h-Hex in the same cell lysates,
suggesting a specificity of NOV as an inhibitor of h-Glu
(Fig. 1b).Fig. 2. Effects of NOVon cellular h-Glu activity. (a) Dose dependence. Two lines
days in the absence or presence of increasing concentrations of NOVand h-Glu act
cultured in the presence of 30 AMNOV up to 7 days (.). A subset of cells was cul
5 days (o). At the time indicated, cells were harvested and h-Glu activity in cell
cells were cultured in the presence of indicated drugs (all at 20 AM) for 4 days and
the same drugs were applied to mouse fibroblasts that express human R201C h-Ga
represents meanF S.E. of three determinations each done in triplicate. *P< 0.05,3.2. Up-regulation of F213I mutant b-Glu activity in GD
cells treated with NOV
To explore an effect of NOV on mutant h-Glu activity,
GD cells with five different genotypes were cultured for 4
days with increasing concentrations of NOV, and h-Glu
activity in cell lysates was determined (Fig. 2a, right). NOV
ica Acta 1689 (2004) 219–228of control cells (left) and five lines of GD cells (right) were cultured for 4
ivity in cell lysates was determined. (b) Time course. F213I/F213I cells were
tured with NOV for 4 days, washed and further cultured without the drug for
lysates was determined. (c) Specificity of the effects of NOV. F213I/F213I
h-Glu activity in cell lysates was determined (left). In separate experiments,
l and h-Gal activity in cell lysates was determined (right). Each point or bar
statistically different from the values in the absence of the drug (t test).
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lines of GD cells, F213I/F213I and F213I/L444P. The
maximum effect of NOV was observed in F213I homozy-
gous cells in which treatment at 30 AM caused a f 6-fold
increase in the enzyme activity, up to f 80% of the basal
activity in control cells. NOV at the same concentration
caused a f 3-fold increase in F213I/L444P cells. There
appeared to be an optimal concentration of NOV, because it
was less potent at a higher concentration (100 AM). NOV
caused no substantial increase in the enzyme activity of GDFig. 3. Effects of NOV on the protein level and intracellular localization of mutan
days. (a) Western blotting. Cell lysates were analyzed by Western blotting with ant
was loaded in each lane. Molecular weights are given on the left (kDa). Densities
meanF S.E. of 3 determinations. *P < 0.05, statistically different from each other
F213I cells with anti-h-Glu and Lysotracker Red. In b and c, shown are the repre
obtained at the same laser intensity and window level. (d) Cell fractionation. Ce
homogenates were subjected to Opti-prep fractionation and each fraction was asse
F213I cells were also subjected to anti-calnexin Western blotting. Each point
experiment. Similar results were obtained in two other experiments.cells with other mutations, indicating a specificity of this
up-regulation for F213I mutant h-Glu. This effect of NOV,
however, was also observed in wild-type h-Glu with a
different dose dependence profile; NOV at 3 AM caused a
f 1.5-fold increase in the two control cell lines but was not
effective at 30 AM (Fig. 2a, left).
Time-course analysis using F213I/F213I cells showed
that in the presence of NOV (30 AM), h-Glu activity
increased in a time-dependent manner and reached a
plateau on day 4. When cells were deprived of NOV ont h-Glu. Cells were cultured with (+) or without ( ) NOV at 30 AM for 4
ibodies against h-Glu or Hex a subunit (left). Twenty micrograms of protein
of h-Glu bands were quantified by densitometry (right). Each bar represents
(t test). (b) Anti-h-Glu immunofluorescence. (c) Double labeling of F213I/
sentative images obtained with a confocal microscope. All the images were
lls were cultured with (.) or without (o) NOV at 30 AM for 4 days. Cell
ssed for activity of h-Glu (upper) or h-Hex (lower). Fractions from F213I/
represents mean values of triplicate determinations obtained in a single
Fig. 3 (continued ).
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still more than three times higher than the basal level on
day 9 (Fig. 2b).
We have shown that both DGJ and NOEV could up-
regulate the activity of R201C mutant h-Gal that was
expressed in fibroblasts derived from h-Gal knockout
mice [11,14]. To test specificity of NOV, first, weexamined whether DGJ or NOEV could up-regulate
F213I h-Glu activity, and found that neither of these
substances caused any changes in the activity (Fig. 2c,
left). Second, we examined whether NOV could up-
regulate the activity of R201C mutant h-Gal, and found
that unlike DGJ and NOEV, NOV had no effect on this
mutant enzyme (Fig. 2c, right).
Fig. 4. Effects of NOV on cellular clearance of 14C-labeled GlcCer. (a)
HPTLC separation of 14C-labeled cellular lipids. Cells were labeled with
14C-serine for 3 days and then chased up to 5 days in the presence or
absence of NOV (30 AM). At the beginning (day 0) and the end (day 5) of
the chase period, cells were harvested and neutral glycolipid fraction was
analyzed by HPTLC. Positions of standard lipids are given on the left
(LacCer, lactosylceramide; CTH, ceramide trihexoside; SM, sphingomye-
lin). (b) Densitometry. Densities of 14C-GlcCer bands on autoradiographs
were quantified using an NIH image software. Values were expressed as
relative to the band density of H11 cell extracts at the beginning of the
chase period (day 0) as 100%. Each bar represents meanF S.E. of three
determinations.
ophysica Acta 1689 (2004) 219–228 2253.3. NOV increased the protein level of F213I mutant b-Glu
and restored its localization in the lysosome
To examine the effect of NOV on the protein level,
cell lysates were subjected to Western blotting with 8E4
monoclonal anti-h-Glu antibody and the protein levels
were estimated by densitometry. This analysis showed
that NOV treatment (30 AM for 4 days) of F213I/F213I
cells caused a significant increase in the protein level of
F213I mutant h-Glu. The same treatment did not increase
the protein levels in N370S/84GG and control cells. As
reported previously [26], the antibody did not recognize
L444P mutant h-Glu. As a control, NOV treatment
caused no changes in the protein levels of Hex a subunit
(Fig. 3a).
Next, we examined intracellular localization of h-Glu
by immunofluorescence and cell fractionation. Anti-h-Glu
staining of control cells showed localization of h-Glu
immunoreactivity in perinuclear punctate structures and
this localization was not affected by NOV treatment. h-
Glu immunoreactivity in F213I/F213I cells was lower
than in control cells and there was no clear localization
in perinuclear punctate structures. When these cells were
treated with NOV, however, the immunoreactivity was
clearly seen in these structures (Fig. 3b). Localization of
F213I mutant h-Glu in the lysosome of NOV-treated cells
was evidenced by co-localization of the immunoreactivity
and a lysosome marker Lysotracker Red (Fig. 3c). h-Glu
immunoreactivity was not detectable in L444P/L444P
cells, indicating the specificity of this antibody staining
(Fig. 3b).
When control cells were subjected to subcellular fraction-
ation on Opti-prep, h-Glu activity was recovered in fractions
#3–5. The same analysis of F213I/F213I cell fractions
showed broad distribution of mutant h-Glu activity with
peaks at #3 and #11. Both peaks were small but were
consistently observed in three independent determinations.
Anti-calnexin Western blotting showed that #11 contained a
high amount of this ER marker protein [27]. NOV treatment
of control cells caused marginal increases (f 1.1-fold) in h-
Glu activity recovered in #3–5. The same treatment of F213I/
F213I cells caused f 4-fold increases in #3–5. As a control,
we measured h-Hex activity in each fraction. Both in control
and F213I/F213I cells, h-Hex activity was recovered in #3–4
and to a lesser degree, in #5–8. h-Hex activity in each
fraction was not affected by NOV treatment in either cell
line (Fig. 3d).
3.4. NOV restored clearance of 14C-labeled GlcCer in
F213I/F213I cells
NOV-induced increase of mutant h-Glu activity in the
lysosome of F213I/F213I cells prompted us to examine
whether NOV could correct abnormal catabolism of
GlcCer in this cell line. By using conventional HPTLC
analysis of cellular lipid extracts, accumulation of GlcCer
H. Lin et al. / Biochimica et Biwas barely detectable in GD skin fibroblasts, most likely
because of the low level of this lipid in these cells (data
not shown). Therefore, we employed metabolic labeling
of cellular glycolipids with [14C]serine and assessed
clearance of 14C-labeled GlcCer. When control cells were
chased for 5 days after the metabolic labeling, the content
of 14C-GlcCer decreased by f 50%. This clearance of
14C-GlcCer was retarded in F213I/F213I cells in which
there was only a f 10% decrease. Inclusion of NOV (30
AM) in the chase medium had no effect in control cells
but accelerated the clearance in F213I/F213I cells. In the
presence of NOV, the content of 14C-GlcCer in F213I/
F213I cells decreased by f 50% and reached a level that
was comparable to that in control cells (Fig. 4b). The
HPTLC analyses showed that besides 14C-GlcCer, clear-
ance of 14C-LacCer was retarded in F213I/F213I cell and
again it was accelerated by NOV (Fig. 4a). In addition,
NOV caused decreases in the levels of 14C-labeled lipids
that corresponded to the positions of CTH, SM and
H. Lin et al. / Biochimica et Biophysica Acta 1689 (2004) 219–228226globoside. The decreases, however, were observed both in
control and F213I/F213I cells and the identities of these
lipids were left unresolved.
3.5. NOV attenuated pH-dependent loss of F213I mutant b-
Glu activity in vitro
Some mutations of lysosomal enzymes affect pH-depen-
dent protein stability [1] and we reported that an a-Gal A
inhibitor DGJ prevented in vitro degradation of mutant a-
Gal A at neutral pH [10]. To examine whether a similar
mechanism underlined NOVeffects on F213I mutant h-Glu,
we compared pH-dependent stability of wild-type and F213I
mutant h-Glu and tested an effect of NOV. In these experi-
ments, we used cell lysates prepared from untreated control
cells and from F213I/F213I cells that had been treated with
NOV at 30 AM for 4 days and further cultured without the
drug for 1 day. When F213I/F213I cell lysates were incu-
bated at pH 7, mutant h-Glu activity was rapidly lost and
there remained less than 5% activity at 1 h. Mutant h-Glu
activity also decreased in acidic conditions at pH 5 or 6, but
f 60% activity retained at 1 h under these conditions. In
contrast, there were only marginal decreases of wild-type h-
Glu activity in control cell lysates and more than 80%Fig. 5. Effects of NOV on pH-dependent loss of F213I mutant h-Glu
activity in vitro. (a) Time course. Cell lysates were incubated at 37 jC in
0.1 M citrate-phosphate buffer at the indicated pH and the enzyme activity
was determined at pH 4.5. (b) Effects of NOV. F213I/F213I cell lysates
were incubated at pH 7 in the absence or presence of NOV at the
concentrations indicated. Each point represents mean values of triplicate
determinations obtained in a single experiment. Values were expressed as
relative to the activity before the incubation (100%). Similar results were
obtained in two other experiments.activity retained after 1-h incubation at every pH (Fig.
5a). The decrease of F213I mutant h-Glu activity at neutral
pH was attenuated by NOV in a dose-dependent manner
(Fig. 5b).4. Discussion
We found in the current study that, when applied to GD
cells with F213I mutations, NOV up-regulated cellular h-
Glu activity (Fig. 2) and accelerated cellular clearance of
GlcCer (Fig. 4). NOV caused a modest but significant
increase in the protein level of the mutant enzyme and
increased its activity in the lysosome (Fig. 3). We also found
pH-dependent loss of F213I mutant h-Glu activity in vitro
and its prevention by NOV (Fig. 5). These findings are most
likely explained by an activity of NOV as a chemical
chaperone to accelerate transport and maturation of F213I
mutant h-Glu. Although details are yet to be proven, we
suppose that F213I mutant h-Glu is degraded in the ER
because of its instability at neutral pH. With the aid of NOV,
this mutant h-Glu is protected from degradation and is
transported to the lysosome where it is stabilized because
of the acidic condition and cellular enzyme activity is
restored. Since effects of NOV on ER enzymes responsible
for h-Glu degradation have not been examined, an alterna-
tive possibility remains to be excluded that the observed
effects of NOV were secondary to inhibition of such
enzyme(s). Although we have shown negative effects of
NOV on some other lysosomal enzymes in vitro (Fig. 1b),
potential effects of this compound on ER enzymes must be
the subject of future studies.
Because NOV is an inhibitor of h-Glu (IC50 = 3 AM,
Fig. 1b), it should inhibit h-Glu activity at the lysosome if
it reaches to an appropriate concentration in this compart-
ment. NOV was most effective in inducing F213I mutant
h-Glu activity at 30 AM in the medium (Fig. 2a), which
was 10 times higher than its IC50 value. NOV at this
concentration, however, failed to inhibit 14C-GlcCer clear-
ance both in control and F213I/F213I cells (Fig. 4). One
possible explanation for this apparent lack of inhibition is
that at 30 AM in the medium, the concentration of NOV in
the lysosome did not rise high enough to inhibit h-Glu
activity (whereas the concentration in the ER did rise high
enough to prevent mutant h-Glu degradation). If this is the
case, the action of NOV as a h-Glu inhibitor may emerge
at inappropriately high concentrations. Indeed, NOV was
less effective at 100 AM in increasing F213I mutant h-Glu
activity (Fig. 2a), although it is yet to be proven that it was
due to this action of NOV. We noticed similar dose
dependence for DGJ to increase mutant a-Gal A activity
in Fabry lymphocytes [10]. Thus, it is apparent that there
is an appropriate concentration range for an enzyme
inhibitor to up-regulate cellular enzyme activities.
The effect of NOV on cellular enzyme activity was
specifically observed in GD cells with F213I mutations
H. Lin et al. / Biochimica et Biophysica Acta 1689 (2004) 219–228 227but not in cells with other point mutations N370S, L444P
and RecNciI (L444P and A456P) (Fig. 2a). Although a
precise molecular basis is left unknown, this selectivity
might depend on the differences in the stability of individ-
ual enzymes, or alternatively, on the differences of NOV-
binding capacities. In this context, the lack of NOV effects
on N370S/84GG cells is in contrast to the reported effects
of NN-DNJ that caused a twofold increase of h-Glu
activity in N370S homozygous cells [12]. It should be
clarified in future studies whether this difference in the
effects of NOV and NN-DNJ is due simply to the cell lines
employed, or to differential binding capacities of N370S
mutant enzyme to these substances.
N370S is the most common mutation in GD patients
and is associated only with type 1 non-neuronopathic GD
[1]. F213I is one of the two prevalent mutations in
Japanese GD patients, found in 15% of alleles [19].
Clinically, patients with F213I mutations have either
non-neuronopathic or neuronopathic GD. NOV may be
of particular therapeutic value in the latter group, since
there is no established therapy against GD brain lesions.
We have shown that NOEV, an isomer of NOV, could
penetrate the blood–brain barrier in mice [14]. It must be
determined in a future study whether NOV penetrates the
blood–brain barrier and exerts its activity on mutant h-
Glu in the brain.
Finally, besides F213I, other h-Glu mutant forms are a
potential target of NOV or related compounds. In this
context, it should be noted that in a report of a neuro-
nopathic GD patient with G202R mutations, ultrastructural
immunohistochemistry revealed the absence of the mutant
protein in the lysosome, despite its abundant presence in
the ER [28]. So far, nojirimycin derivatives have been an
only known class of carbohydrate mimics with chemical
chaperone activity for lysosomal enzymes [10–12]. To-
gether with NOEV [14], NOV represents a novel class of
carbohydrate mimics with a potential chemical chaperone
activity. It is a subject of future studies to test whether
NOV and related compounds work as a chemical chaperone
for other h-Glu mutant forms, and further for other mutant
lysosomal enzymes.Acknowledgements
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